Dispatch · June 27, 2026 · 8 min read

Your July 2026 Men's GLP-1 Roadmap: What's New, What's Changed, What's Next

The first half of 2026 delivered more changes to the GLP-1 landscape than the previous two years combined. New medications reached market, prices dropped dramatically, landmark research reshaped what we know about these drugs, and access expanded through Medicare and telehealth. Here's your comprehensive mid-year update.

What's New in 2026

Foundayo (orforglipron) — FDA approved April 2026. The first small-molecule oral GLP-1 eliminated the injection barrier for good. Unlike the existing oral semaglutide (Rybelsus), which requires fasting and careful timing, Foundayo can be taken with food and has fewer absorption restrictions. For men who refused weekly injections, this is a game-changer.

Medicare GLP-1 Bridge — launching July 1, 2026. Medicare Part D beneficiaries can now access brand-name Wegovy, Zepbound, and Foundayo for $50 per month. This is the most significant access expansion since GLP-1s went mainstream.

Semaglutide epigenetic aging study — Nature Communications, May 2026. UC San Diego researchers published the first randomized, controlled evidence that semaglutide slows biological aging by approximately 9% on epigenetic clocks. Early data, but a major signal that these medications may have longevity benefits beyond metabolic health.

Major developments in H1 2026: oral GLP-1 approval, Medicare coverage, and anti-aging evidence

What Changed

Pricing collapsed. Competition among telehealth providers drove compounded semaglutide prices below $100/month at several platforms. Combined with Medicare's $50 program and manufacturer savings cards, the cost barrier that defined 2024-2025 has largely evaporated.

ENDO 2026 rewrote the male hormone story. The systematic review confirming GLP-1s don't harm male fertility — and may improve testosterone and sperm quality — changes the clinical conversation for millions of men. The data supports GLP-1 therapy as a first-line approach for obesity-related low testosterone, ahead of TRT in many cases.

The 503B regulatory landscape shifted. The FDA's comment period for excluding semaglutide and tirzepatide from 503B compounding closed June 29. A final decision will reshape the compounded medication market. 503A pharmacies remain unaffected regardless of the outcome.

Category	January 2026	July 2026
Oral GLP-1 options	Rybelsus only (absorption issues)	Foundayo + Ozempic tablets available
Lowest compounded sema price	~$149/mo	~$99/mo at some providers
Medicare coverage	Limited to diabetes	$50/mo Bridge program for obesity
Male fertility data	Limited, mostly theoretical	5 RCTs confirming safety + improvement
Anti-aging evidence	Animal studies, observational	First human RCT (UC San Diego)

What's Next (H2 2026)

CagriSema. Novo Nordisk's combination of semaglutide and cagrilintide — designed to amplify weight loss beyond what either drug achieves alone — is in late-stage trials with results expected this year. If approved, it would become the most potent weight loss medication available.

Elecoglipron data maturation. The SOLSTICE trial (published in The Lancet, June 2026) showed promising results for this new oral small-molecule GLP-1 from Mass General Brigham. If it reaches market at competitive pricing, the oral GLP-1 category expands further.

Survodutide for NASH/MASH. Boehringer Ingelheim's Phase 3 results for this GLP-1/glucagon dual agonist targeting liver disease could expand the GLP-1 category into hepatology — relevant for men with fatty liver disease.

503B regulatory decision. The FDA's final ruling on compounding exclusions will likely come in late 2026 or early 2027. Providers are already positioning with 503A alternatives and brand-name options.

Your Action Items for July

If you're already on GLP-1 therapy: Check whether your provider's pricing remains competitive — the market has shifted and you may be paying more than necessary. Ask about body composition monitoring (DXA scans) to track muscle vs. fat loss. Review your protein intake against the updated 1.2-1.6 g/kg/day target.

If you're considering starting: 2026 is the best year to begin treatment. More options, lower prices, stronger evidence, and expanding coverage mean fewer reasons to wait. Oral options eliminate the injection barrier. Medicare coverage removes the cost barrier for eligible men over 65.

If you're on TRT for obesity-related low T: Discuss the ENDO 2026 fertility data with your provider. GLP-1 therapy may be a better first-line approach that preserves fertility and addresses the root cause.